research_lead_image2.png

Clinical Trials

Human clinical trials are a critical phase to bringing safe and effective treatments to market. Many tests are conducted before the clinical trial stage to determine whether potential treatments are appropriate for testing in people. It is through clinical trials that safe and effective drugs, therapies and ultimately, a cure for alopecia areata will be discovered.

By participating in a clinical trial, you play an important role in the fight to treat and cure alopecia areata. The decision to participate, however, is very personal and should be made only after speaking with your health care provider and other individuals you trust. You can stop participation in a clinical trial at any time if new concerns arise or you lose confidence that its potential benefits outweigh its risks.

The Alopecia Areata Registry, Biobank and Clinical Trials Network (Registry) will be utilized to solicit participants for future clinical trials.  If you would like to help, please join the Registry and add to our nearly 10,000 registrants.

Clinical Trial Resources

ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings. Visit ClinicalTrials.gov to review clinical trials that are enrolling around the country on alopecia areata and other diseases.

Current Clinical Trials

New York Presbyterian Hospital, Columbia University

Department of Dermatology, Clinical Research Unit

Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a medication, given as a subcutaneous injection that acts on the immune system and may reverse hair loss. Enrollment for this study has been completed. This study is ongoing but no longer recruiting participants. To learn more, click here.

New York Presbyterian Hospital, Columbia University

Department of Dermatology, Clinical Research Unit

Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a new medication taken as a pill that acts on the immune system and may reverse hair loss. Enrollment for this study has been completed. This study is ongoing but no longer recruiting participants. To learn more, click here.

New York Presbyterian Hospital, Columbia University

Department of Dermatology, Clinical Research Unit

Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions. Enrollment for this study has been completed. This study is ongoing but no longer recruiting participants. To learn more, click here.

TrialNetType 1 Diabetes TrialNet (TrialNet) is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. Alopecia Areata families have a higher incidence of other autoimmune diseases, including type 1 diabetes (T1D). Relatives of someone with T1D have 15 to 20 times the risk to develop the disease.

TrialNet is offering T1D risk screening to blood relatives of someone with T1D through a blood test performed at no cost and available anywhere in the US. If there is a person with T1D in your family (defined as someone with diabetes diagnosed before age 40 who was started on insulin within the first year), then you or other relatives between the ages of 1 and 45 may be eligible for screening.

Family members who are identified at high risk through blood testing are offered close monitoring and, if eligible, the opportunity to participate in T1D prevention trials.

We want to put an end to type 1 diabetes and need your help to do so. Click here to learn more about T1D risk screening and T1D prevention research. You can also call 1-800-425-8361 or trialnetinfo [at] epi.usf.edu (email TrialNet )for more information.

Disclaimer: NAAF provides research notices as an informational service to its members. NAAF is not conducting the study. This information does not represent a NAAF endorsement, but rather makes you aware that clinical studies are available for your participation if you choose. If you are presently under the care of a physician for alopecia areata, or other conditions, you should discuss this study with your doctor before altering your treatment program. NAAF is not responsible for any adverse outcomes.